2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
19
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Interventions
binimetinib
2
Watchful Waiting
2
Sodium Chloride
2
Aminolevulinic Acid
2
palbociclib
1
methyl 5-aminolevulinate
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Spironolactone
1
Radiotherapy
1
Radiation
1
Photochemotherapy
1
Paclitaxel
1
Low-Level Light Therapy
1
Leuprolide
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Fluorouracil
1
Floderm topical cream
1
Everolimus
1
Equipment and Supplies
1
Docetaxel
1
Dacarbazine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Diseases
×
exemestane
×
Clear all
NCT01743560
2019-07-18
4EVERUK
Novartis
Phase 4
Completed
52 enrolled
16 charts